OCREVUS Roche Products Pty Ltd
Product name
OCREVUS
Sponsor
Accepted date
Jan-2026
Active ingredients
ocrelizumab
Proposed indication
OCREVUS (ocrelizumab) is proposed for the treatment of:
-adults with relapsing forms of multiple sclerosis (MS). It is proposed that it slows down the worsening of physical disability and reduces how often relapses happen.
-adults with primary progressive multiple sclerosis (PPMS) by slowing the progression of physical disability.
-children aged 10 and older with relapsing-remitting multiple sclerosis (RRMS).
-adults with relapsing forms of multiple sclerosis (MS). It is proposed that it slows down the worsening of physical disability and reduces how often relapses happen.
-adults with primary progressive multiple sclerosis (PPMS) by slowing the progression of physical disability.
-children aged 10 and older with relapsing-remitting multiple sclerosis (RRMS).
Application type
C (new indication)
Publication date
Jan-2026